Congenital Heart Disease - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 60

Congenital Heart Disease - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Congenital Heart Disease - Pipeline Review, H2 2011', provides an overview of the Congenital Heart Disease therapeutic pipeline. This report provides information on the therapeutic development for Congenital Heart Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congenital Heart Disease. 'Congenital Heart Disease - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Congenital Heart Disease.
- A review of the Congenital Heart Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Congenital Heart Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Congenital Heart Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Congenital Heart Disease pipeline depth and focus of Congenital Heart Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Congenital Heart Disease Therapeutic Products under Development, Key Players in Congenital Heart Disease Therapeutics, Congenital Heart Disease Pipeline Overview, Congenital Heart Disease Pipeline, Congenital Heart Disease Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Congenital Heart Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Congenital Heart Disease
Congenital Heart Disease Therapeutics under Development by Companies
Congenital Heart Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Congenital Heart Disease Therapeutics - Products under Development by Companies
Congenital Heart Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Congenital Heart Disease Therapeutics Development
Mesoblast Ltd
Palatin Technologies, Inc.
Genetrix SL
Cardioxyl Pharmaceuticals, Inc.
PLx Pharma Inc.
Asklepion Pharmaceuticals, LLC.
Congenital Heart Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PL-3994 - Drug Profile
Citrulline - Drug Profile
PL 4500 Indomethacin-PC - Drug Profile
Spironolactone - Drug Profile
Phenoxybenzamine - Drug Profile
Enalapril - Drug Profile
Nitric Oxide - Drug Profile
Citrupress IV - Drug Profile
Hydrocortisone - Drug Profile
Pentoxifylline - Drug Profile
Indomethacin - Drug Profile
IVIG - Drug Profile
N-Acetylcysteine - Drug Profile
Tadalafil - Drug Profile
Stromal-derived factor 1 - Drug Profile
Indomethcin - Drug Profile
Adenosine - Drug Profile
Ibuprofen - Drug Profile
Tracleer - Drug Profile
Nitroxyl Donor For CHF - Drug Profile
Ibuprofen - Drug Profile
Ctx101 - Drug Profile
Paracetamol - Drug Profile
Fenoldopam - Drug Profile
Bosentan - Drug Profile
Autologous Cardiac Progenitor Cell Transplantation - Drug Profile
Congenital Heart Disease Therapeutics – Drug Profile Updates
Congenital Heart Disease Therapeutics - Discontinued Products
Congenital Heart Disease - Featured News
Feb 06, 2009: PLx Receives $0.73 Million In Funding From US Army In SBIR Phase II Award
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Congenital Heart Disease, H2 2011
Products under Development for Congenital Heart Disease – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mesoblast Ltd, H2 2011
Palatin Technologies, Inc., H2 2011
Genetrix SL, H2 2011
Cardioxyl Pharmaceuticals, Inc., H2 2011
PLx Pharma Inc., H2 2011
Asklepion Pharmaceuticals, LLC., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Congenital Heart Disease Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Congenital Heart Disease, H2 2011
Products under Development for Congenital Heart Disease – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) - Pipeline Review, H2 2011
• Acute Heart Failure - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Muscular Dystrophy - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012